Company Zai Lab Limited

ZLAB

US98887Q1040

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Zai Lab Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:02 2024-04-23 pm EDT			5-day change	1st Jan Change
15.12 ^USD	+0.87%		+10.20%	-44.68%

Apr. 17	Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	MT
Apr. 11	Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024	MT

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

Number of employees: 2,175

USD in Million	2022	Weight	2023	Weight	Delta
Innovative Therapies 100.0 %	215	100.0 %	267	100.0 %	+24.03%

USD in Million	2022	Weight	2023	Weight	Delta
Greater China and United States 100.0 %	215	100.0 %	267	100.0 %	+24.03%

Managers	Title	Age	Since
Ying Du CEO	Chief Executive Officer	59	14-03-31
Ya jing Chen DFI	Director of Finance/CFO	56	21-08-31
Joshua Smiley PSD	President	54	22-07-31
Peter Huang CTO	Chief Tech/Sci/R&D Officer	-	22-11-07
Ann Beasley CMP	Compliance Officer	-	20-10-31
James Yan CTO	Chief Tech/Sci/R&D Officer	60	20-03-31
Ning Xu CTO	Chief Tech/Sci/R&D Officer	59	13-12-31
Lina Zhang SAM	Sales & Marketing	-	-
Li Ni Ou Yang SEC	Corporate Secretary	-	22-06-26
F. Edmondson LAW	General Counsel	58	20-08-06

Members of the board	Title	Age	Since
John D. Diekman BRD	Director/Board Member	81	16-12-31
Peter Wirth BRD	Director/Board Member	73	16-12-31
Lonnie Moulder BRD	Director/Board Member	66	18-12-31
Wing Yu Leung BRD	Director/Board Member	53	14-07-31
William Lis BRD	Director/Board Member	60	18-09-30
Kai Xian Chen BRD	Director/Board Member	79	18-08-13
Ying Du CEO	Chief Executive Officer	59	14-03-31
Richard Gaynor BRD	Director/Board Member	74	21-11-18
Scott Morrison BRD	Director/Board Member	66	21-10-12
Michel Vounatsos BRD	Director/Board Member	62	23-01-06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	977,151,270	879,293,014 ( 89.99 %)	4,912,200 ( 0.5027 %)	89.99 %

Name	Equities	%	Valuation
Qiming Venture Partners Ltd. 7.986 %	79,229,320	7.986 %	131 M $
Wellington Management Co. LLP 6.129 %	60,805,022	6.129 %	100 M $
Wellington Management International Ltd. 2.041 %	20,249,300	2.041 %	33 M $
UBS Asset Management Switzerland AG 1.908 %	18,926,266	1.908 %	31 M $
Bosera Asset Management Co., Ltd. 0.7694 %	7,633,300	0.7694 %	13 M $
Capital Research & Management Co. (World Investors) 0.5470 %	5,426,290	0.5470 %	9 M $
Peter Wirth 0.3646 %	3,616,660	0.3646 %	6 M $
Fidelity Management & Research (Hong Kong) Ltd. 0.3093 %	3,068,300	0.3093 %	5 M $
HuaAn Fund Management Co., Ltd. 0.2538 %	2,518,100	0.2538 %	4 M $
Fidelity Management & Research (Japan) Ltd. 0.2472 %	2,452,600	0.2472 %	4 M $

Name	Equities	%	Valuation
Wellington Management Co. LLP 5.379 %	5,336,457	5.379 %	85 M $
Capital Research & Management Co. (World Investors) 5.260 %	5,218,843	5.260 %	84 M $
Janus Henderson Investors US LLC 4.073 %	4,040,282	4.073 %	65 M $
T. Rowe Price International Ltd. 2.726 %	2,704,455	2.726 %	43 M $
Woodline Partners LP 2.035 %	2,018,527	2.035 %	32 M $
Invesco Advisers, Inc. 1.909 %	1,893,529	1.909 %	30 M $
Viking Global Investors LP 1.884 %	1,869,283	1.884 %	30 M $
Segantii Capital Management Ltd. 1.701 %	1,687,569	1.701 %	27 M $
BAMCO, Inc. 1.503 %	1,490,874	1.503 %	24 M $
Fidelity Management & Research Co. LLC 1.247 %	1,236,927	1.247 %	20 M $

Zai Lab Ltd.

Jinchuang Plaza Building 1, 4/F

201210, Shanghai

+86 21 6163 2588

http://www.zailaboratory.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.99 USD

Average target price

52.5 USD

Spread / Average Target

+250.27%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
ZAI LAB LIMITED	-44.68%	1.48B
CSL LIMITED	-1.42%	85.68B
SAMSUNG BIOLOGICS CO.,LTD.	+4.08%	41.4B
BIOGEN INC.	-25.35%	28.22B
UCB	+54.31%	24.64B
BIOMARIN PHARMACEUTICAL INC.	-4.52%	16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.09%	13.29B
INCYTE CORPORATION	-17.77%	11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.10%	11.65B
SWEDISH ORPHAN BIOVITRUM AB	+0.75%	8.18B

Biopharmaceuticals